← Back to Clinical Trials
Recruiting NCT05179928

NCT05179928 Erector Spinae Plane Block Versus Rectus Sheath Block for Postoperative Analgesia After Supraumbilical Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05179928
Status Recruiting
Phase
Sponsor Damanhour Teaching Hospital
Condition Post Operative Pain
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-08-01
Primary Completion 2026-02-15

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Erector Spinae Plane Block (ESPB)Rectus Sheath Block (RSB)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-08-01 with a primary completion date of 2026-02-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Objectives: To compare the effectiveness of erector spinae plane block (ESPB) and rectus sheath block (RSB) in providing postoperative analgesia after supraumbilical surgery in adult patients and their impact on the patient's outcomes. Background: Supraumbilical surgery for hernia repair is the second-most-popular after surgical inguinal hernia repair and is accompanied by moderate to severe postoperative pain, so patients always require large doses of opioids within the first postoperative day. Because opioids have several adverse effects such as drowsiness, pruritus, nausea, and vomiting, regional analgesic techniques are an essential component of postoperative opioid-sparing analgesia. Previous studies have shown that regional analgesic techniques after abdominal wall surgeries can be an essential element of a postoperative pain management strategy with minimal adverse effects and hemodynamic responses. ESPB provides both somatic and visceral analgesia to the abdominal wall, through the blockade of the anterior rami of spinal nerves and the rami communicants involving sympathetic nerve fibers. RSB provides analgesia to the anterior abdominal wall from the xiphoid process to the symphysis pubis, through the blockade of the anterior rami of the 7th to 12th intercostal nerves. The dermatomal distribution of ESPB and RSB makes them ideal regional analgesic techniques after abdominal surgery, and to our knowledge, there were no previous trials that studied the difference between them. Patients and Methods: This was a prospective, randomized (1:1), double-blind clinical trial on 60 patients scheduled for elective supraumbilical surgery under general anesthesia at our hospital. Patients will be randomly allocated into two equal groups (30 patients each) and will receive: in group E; general anesthesia with postoperative bilateral ultrasound-guided ESPB, whereas in group R; general anesthesia with postoperative bilateral ultrasound-guided RSB.

Eligibility Criteria

Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status ≤ II * Age from 21 to 60 years * Body Mass Index (BMI) \< 35 kg/m² Exclusion Criteria: * American Society of Anesthesiologists (ASA) physical status \> II * Age \< 21 years or \> 60 years * Body Mass Index (BMI) ≥ 35 * Local infection at the puncture site * Altered mental status * Pregnant women * Allergy to study drugs * Chronic pain * Coagulation abnormalities or on anticoagulants * Severe hepatic or kidney disease

Contact & Investigator

Central Contact

Ahmed M Shaat, MD

✉ ahmedshaat99@gmail.com

📞 00201223482709

Principal Investigator

Ahmed M Shaat, MD

PRINCIPAL INVESTIGATOR

Damanhour Teaching Hospital

Frequently Asked Questions

Who can join the NCT05179928 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 60 Years, studying Post Operative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05179928 currently recruiting?

Yes, NCT05179928 is actively recruiting participants. Contact the research team at ahmedshaat99@gmail.com for enrollment information.

Where is the NCT05179928 trial being conducted?

This trial is being conducted at Damanhūr, Egypt.

Who is sponsoring the NCT05179928 clinical trial?

NCT05179928 is sponsored by Damanhour Teaching Hospital. The principal investigator is Ahmed M Shaat, MD at Damanhour Teaching Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology